At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
UNCY Unicycive Therapeutics, Inc.
Closed Good Friday 04-17 16:00:00 EDT
0.6003
+0.0023
+0.38%
盘后0.6200
+0.0197+3.28%
19:53 EDT
| High0.6103 | Low0.5975 | Vol186.60K |
| Open0.5980 | D1 Closing0.5980 | Amplitude2.14% |
| Mkt Cap71.86M | Tradable Cap42.38M | Total Shares119.71M |
| T/O112.34K | T/O Rate0.26% | Tradable Shares70.60M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
Buy Rating for Unicycive Therapeutics: Competitive Advantages of Oxylanthanum Carbonate in Hyperphosphatemia Treatment
TIPRANKS · 04-11
Unicycive Therapeutics: Buy Rating on Imminent FDA Approval and Market Potential of Oxylanthanum Carbonate
TIPRANKS · 04-11
Unicycive presents new patient-level data from Phase 2 study of OLC
TIPRANKS · 04-10
Unicycive Presents New Patient-Level Data Underscoring Challenges Faced with Current Phosphate Binders and Highlighting the Potential of Oxylanthanum Carbonate to Address Barriers to Adherence for Patients with Hyperphosphatemia on Dialysis
GlobeNewswire · 04-10
Unicycive Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $7.5 From $4
THOMSON REUTERS · 04-01
Unicycive Therapeutics reports FY24 EPS (56c), consensus (51c)
TIPRANKS · 03-31
Unicycive Therapeutics Inc: Believes That It Has Sufficient Resources to Fund Planned Operations Into 2026
THOMSON REUTERS · 03-31
Unicycive Therapeutics FY 2024 GAAP EPS $(0.56) Misses $(0.50) Estimate, As Of December 31, 2024, Cash And Cash Equivalents Of $26.1M, Sufficient To Fund Planned Operations Into 2026
Benzinga · 03-31
Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire · 03-31
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones · 03-27
DaVita Stock Declines 1.2% in 3 Months: Here's How to Play
Zacks · 03-26
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones · 03-24
Unicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of Hyperphosphatemia
THOMSON REUTERS · 03-13
Noble Financial Sticks to Its Buy Rating for Unicycive Therapeutics (UNCY)
TIPRANKS · 02-21
Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360
GlobeNewswire · 02-20
Unicycive Therapeutics Price Target Maintained With a $4.00/Share by HC Wainwright & Co.
Dow Jones · 01-29
Buy Rating for Unicycive Therapeutics Driven by Promising OLC Treatment and Reduced Pill Burden
TIPRANKS · 01-29
Unicycive announces publication of patient perspectives on phosphate management
TIPRANKS · 01-28
Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science
GlobeNewswire · 01-28
Positive Buy Recommendation for Unicycive Therapeutics Driven by Promising Trial Results and Revenue Forecasts
TIPRANKS · 01-08
Introduction
Company Name.
Unicycive Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App